Indiana Federal Judge: Lilly Prevails On Indirect Patent Infringement Claim

Mealey's (August 28, 2015, 12:08 PM EDT) -- INDIANAPOLIS — Citing the U.S. Supreme Court’s ruling on divided infringement in Limelight Networks Inc. v. Akamai Technologies Inc. (134 S. Ct. 2111 [2014]) and a recent en banc Federal Circuit U.S. Court of Appeals ruling in the same case, an Indiana federal judge on Aug. 25 found that abbreviated new drug applications (ANDAs) for generic Alimta would indirectly infringe an Eli Lilly and Co. patent (Eli Lilly and Company v. Teva Parenteral Medicines Inc. et al., No. 10-1376, S.D. Ind.; 2015 U.S. Dist. LEXIS 112221)....
To view the full article, register now.